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Background: Micronutrient deficiencies (MNDs) are a chronic lack of vitamins and minerals and constitute a huge
public health problem. MNDs have severe health consequences and are particularly harmful during early childhood
due to their impact on the physical and cognitive development. We estimate the costs of illness due to iron
deficiency (IDA), vitamin A deficiency (VAD) and zinc deficiency (ZnD) in 2 age groups (6–23 and 24–59 months) of
Filipino children by socio-economic strata in 2008.
Methods: We build a health economic model simulating the consequences of MNDs in childhood over the entire
lifetime. The model is based on a health survey and a nutrition survey carried out in 2008. The sample populations
are first structured into 10 socio-economic strata (SES) and 2 age groups. Health consequences of MNDs are
modelled based on information extracted from literature. Direct medical costs, production losses and intangible
costs are computed and long term costs are discounted to present value.
Results: Total lifetime costs of IDA, VAD and ZnD amounted to direct medical costs of 30 million dollars,
production losses of 618 million dollars and intangible costs of 122,138 disability adjusted life years (DALYs). These
costs can be interpreted as the lifetime costs of a 1-year cohort affected by MNDs between the age of 6–59 months.
Direct medical costs are dominated by costs due to ZnD (89% of total), production losses by losses in future lifetime
(90% of total) and intangible costs by premature death (47% of total DALY losses) and losses in future lifetime
(43%). Costs of MNDs differ considerably between SES as costs in the poorest third of the households are 5 times
higher than in the wealthiest third.
Conclusions: MNDs lead to substantial costs in 6-59-month-old children in the Philippines. Costs are highly concentrated
in the lower SES and in children 6–23 months old. These results may have important implications for the design,
evaluation and choice of the most effective and cost-effective policies aimed at the reduction of MNDs.
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Micronutrient deficiencies (MNDs) are a chronic lack of
vitamins and minerals and constitute a huge public
health problem. According to WHO, worldwide nearly
one in two preschool children suffer from anemia, many
of them because of iron deficiency [1,2], and nearly 100
million preschool children suffer from VAD [3]. Severe
and widespread deficiencies also prevail for iodine, zinc
and a number of other micronutrients [4]. MNDs are
sometimes called hidden hunger, as they are not as vis-
ible as malnutrition due to insufficient calorie and pro-
tein intake. They have severe health consequences and
are particularly harmful during pregnancy and early
childhood due to their impact on the physical and cogni-
tive development of children [5,6].
Previous studies have shown that the impact of MNDs
on public health can be substantial for countries with
high prevalence rates [7-11]. Studies evaluating the im-
pact of a disease are called “cost-of-illness studies” when
they focus on its economic costs in terms of medical
costs and productivity losses and “burden-of-disease
studies” when they focus on its human costs in terms of
years lived with disability and years of life lost. These
studies are often carried out in order to draw the atten-
tion of policy makers to the impact of specific diseases
and can thus be of utmost importance for public health
priority setting. For MND this is specifically relevant, as
effective interventions exist [12-15]. UN development
agencies and NGOs have rated interventions focussing
on MNDs as a top development priority and these inter-
ventions are part of the efforts to reach the United Na-
tions Millennium Development Goals [16,17].
This study is part of a more extensive project on the
cost-effectiveness of food fortification for 6-59-month-
old children. In a first step we examined whether food
fortification is effective in controlled trials [12]. In a sec-
ond step, which is the subject of the present study, we
develop a model of cost consequences of MNDs. In a
third step we will evaluate the cost-effectiveness of food
fortification interventions in the Philippines.
We chose the Philippines for our cost-of-illness study be-
cause it is a large country in which MNDs are still consid-
ered to be a public health issue. Furthermore, detailed data
on the nutritional status of the population is available.
In this study we estimate the economic and human
costs of illness due to iron, vitamin A and zinc deficien-
cies in 6-59-month-old Filipino children by socio-
economic strata with a model simulating the lifetime
consequences of MNDs.
Methods
Ethics statement
The datasets used in this study were obtained from
MEASURE DHS [18] and from FNRI [19]. Full review ofthis study from an institutional review board was not
sought as the datasets were anonymous and they are
available for public use with no identifiable information
on the survey participants.
Aim and study concept
This study aims to quantify the cost of MNDs in the
Philippines by comparing the current nutritional situ-
ation with a hypothetical scenario in which all children
have a sufficient MN intake, either through their diet or
through MN supplementation. We build a health eco-
nomic model simulating the consequences of MNDs in
childhood over the entire lifetime. Costs of MNDs in
adulthood are only considered if they are the conse-
quences of childhood micronutrient malnutrition. The
model is referenced to the year 2008 for which we have
the results of a major health survey, the 2008 National
Demographic and Health Survey (DHS) [18], and of a
major nutrition survey, the 2008 National Nutrition Sur-
vey (NNS) [19]. The model was developed both in
Microsoft Excel and R and its technical details are de-
scribed in Additional file 1.
Study design
The study follows a bottom-up, incidence-based design
with a societal perspective and a lifetime horizon.
Bottom-up means that costs are first calculated on the
data collected from single households contacted in the
2008 DHS and NNS surveys and then extrapolated to
the total population. Incidence-based means that the
model computes the lifetime costs for a one-year cohort
of children 6–17 months old in 2008. Societal perspective
means that all the costs occurring in the society are con-
sidered. These costs include disease related health care ex-
penditures (direct medical costs), current and future
income losses of individuals of working age due to ab-
sence from work and reduced productivity (production
losses) and quality and quantity of life years lost (intan-
gible costs) (Figure 1).
Study population
Our model differentiates 6-59-month-old children by 10
socio-economic strata (SES) (1 = lowest decile of house-
holds, 10 = highest decile) and two age groups (6–
23 months and 24–59 months). Levels of MNDs as well as
their consequences are particularly severe in these age
groups as the body stores of micronutrients tend to be
progressively exhausted at the age of 6 months and the
child’s diet is often not adequate to meet the great need
for micronutrient intake in periods of rapid growth. Al-
though children below this age range may also suffer
from MNDs [20] they are excluded from the analysis as
our study is part of a more extensive project focussing
on nutritional interventions for 6-59-month-old children.
Figure 1 General structure of study. The DHS and NNS sample populations are first structured into 10 socio-economic strata (SES) and 2 age
groups of children per SES (6–23 months and 24-59 months). In a second step the MNDs of children are assessed in each of these groups. In a
third step the lifetime health consequences of these MNDs are modelled based on information extracted from literature. In a final step the direct
medical costs, production losses and intangible costs caused by these health consequences are computed and long-term costs are discounted
to present value.
Table 1 Cut-off levels for MNDs
Micronutrient
deficiency
Blood value Cut-off level Source
Iron deficiency
anemia
Hemoglobin 100 [g/L] for moderate
and 70 [g/L] for severe
anemia
[26]
Vitamin A Serum retinol 20 [μg/dL] [3]
Zinc Serum zinc 65 [μg/dL] [19]
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up to 6 months of age [21]. Meanwhile, children older
than 59 months are excluded from the analysis as they
have a reduced risk of MNDs [22].
Both the DHS [18], carried out by the Philippines Na-
tional Statistics Office, and the NNS [19], carried out by
the Philippines Food and Nutrition Research Institute
(FNRI), are large and representative population surveys
with 12,469 respectively 36,634 households successfully
contacted in 2008. We had access to the complete NNS
and DHS [23] data. Households from the two surveys
were stratified by deciles into 10 SES. SES were defined
by a wealth index similar to the conventional DHS
wealth index [24] but based only on household charac-
teristics contained in the NNS as well as in the DHS.
We use the following terminology for the populations
considered: The sample population consists of the 6–
59 months old children from the DHS and NNS. The
model population is the sample population extrapolated
to the total population representing all 6-59-month-old
Filipino children in 2008. The model cohort is the 1-
year-cohort of 6-17-month-old children from the model
population for which lifetime cost consequences of
MNDs are calculated. Costs are calculated separately for
MNDs at the age of 6–23 months and 24–59 months.
Prevalence of MNDs
The MNDs considered in this study are those of iron,
vitamin A and zinc, as the health consequences of these
deficiencies are well documented. We exclude iodine de-
ficiency, although its health consequences are also well
documented, because iodine fortification is focused on
salt as a carrier [25] and not on milk and cereals, whichwill be the fortified foods considered in the third part of
our study. The study ignores the health consequences of
iron-deficiency in non-anemic children.
Information on the prevalence of MNDs was extracted
from the 2008 NNS for the 2 age groups over the 10
SES. Prevalence rates are calculated by assuming a nor-
mal distribution defined by the mean and the standard
deviations (SD) of the blood values provided by FNRI
and applying the cut-off levels reported in Table 1. The
probability of being below the cut-off level is equal to
the prevalence rate of MNDs in the population. Preva-
lence of anemia was calculated as the proportion of chil-
dren with hemoglobin level below WHO cut-off levels
[26] for moderate and severe anemia (Table 1). 60% of
cases of anemia were attributed to iron deficiency
anemia (IDA) [27]. Vitamin A deficiency (VAD) was
measured with serum retinol level and zinc deficiency
(ZnD) with serum zinc level [19]. Serum zinc has been
criticized as a measure of ZnD, as ZnD may be present
even if the serum level is in the normal range. Nonethe-
less serum zinc is the best known measure of deficiency
and has been shown to be a reasonable indicator of defi-
ciency at a population level [28].
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as mean and SD for each of the 20 groups of children.
Although this information is mostly based on reasonable
sample sizes of up to 250 children per group, some
groups have a small sample size with only 15 observa-
tions in the smallest group. In order to be able to ex-
trapolate the sample data to the whole population,
without magnifying uncertainty due to limited sample
size, we smoothed the distribution of these group means.
The levels of MNDs in the 20 groups correspond to the
average group specific deficiency levels measured in the
NNS.
Attribution of health consequences
Whenever possible, the attribution of health conse-
quences to MNDs is based on systematic reviews of the
effects of MN supplementation trials for children aged
6–59 months. We assume that MN supplementation tri-
als were designed to fill the gap of MN intake (e.g. in
terms of adequate intake) due to the insufficient diet of
the children and thus eliminate all the adverse health
consequences of MNDs, an approach also applied in
previous research [29]. The health consequences of
MNDs thus correspond to the difference in health status
of the intervention and the control group in the supple-
mentation trials.
Some of the health effects of MNDs are calculated by at-
tributing a fraction of the current prevalence of diarrhea
and lower respiratory diseases to a specific micronutrient.
We calculate the population attributable fractions (PAF)
based on relative risks (RR) extracted from the literature
by applying Levin’s classical formula [30]. These PAF are
then applied to the current mortality and prevalence of
relevant diseases in order to calculate the number of epi-
sodes attributable to MND. Prevalence of measles is not
covered by DHS and therefore estimated using the nation-
wide prevalence rates and the immunization rates by
group according to DHS data. Child mortality rates were
calculated according to the procedure used in the DHS re-
port [18]. The influence of MNDs on mortality is modeled
as influence on all-cause mortality. The effect may be dir-
ect via diseases associated with MNDs (diarrhea, lower re-
spiratory disease, and measles) or indirect via increased
incidence of other diseases.
Attribution of costs to health consequences
Attribution of costs to the health consequences of
MNDs is based on information extracted from the DHS,
literature and other sources. These costs include costs in
the immediate occurrence of the disease as well as long-
term costs due to the lifetime consequences of impaired
physical and mental development. Intangible costs are
measured in DALYs, while monetary costs are measured
in US Dollars (USD). Quantities originally measured inPhilippine Pesos (PHP) were converted into USD using
an average 2008 exchange rate.
Calculation of direct medical costs is mainly based on
the DHS [18]. The households interviewed in the survey
were asked for the costs borne in the treatment of diar-
rhea and lower respiratory infections of their children,
which are both frequent adverse health consequences of
MNDs. We assume that the specified costs in the DHS
represent out-of-pocket expenditure of the households.
As health service providers in the Philippines are in part
financed by government agencies, we increase these out-
of-pocket expenditures with a factor corresponding to
the public share in overall health expenditures [31,32].
Production losses are calculated according to the hu-
man capital approach and thus correspond to the
current and future gross monetary income losses. They
include income losses of parents who cannot work be-
cause they have to take care of their sick children and
the lifetime income losses due to impaired physical and
cognitive development and premature death of children.
We assume that income losses of parents only occur in
households in which both parents work. Whereas
current production losses are valued with SES specific
incomes, future losses are all valued with an average in-
come. In order to account for future economic growth,
we assume a yearly increase in wages of 1.66%, corre-
sponding to the average growth rate of real GDP per
capita in the years 1990–2011 [33].
Intangible costs are calculated as Disability Adjusted
Life Years (DALYs) lost without applying age weights
[34]. DALYs are lost due to current illness, premature
death and future permanent disabilities. We do not
quantify DALY losses in monetary terms, as this is often
criticised as ethically and methodologically questionable
[35].
Production losses and intangible costs can be consid-
ered as two separate and non-overlapping dimensions of
the costs of MNDs as recent research has shown that
double counting of losses considered in both cost di-
mensions is negligible [36,37].
Discounting future losses to present value
Future production losses have to be discounted to their
present value because a dollar today is worth more than
a dollar in 20 or 30 years (Figure 2). We apply a discount
rate of 3% which is a widely accepted value in cost-of-
illness studies [38].
For discounting of future life years we follow the Glo-
bal Burden of Disease Report [39], which discounts fu-
ture DALY losses with a 3% rate in the baseline analysis
but reports undiscounted DALYs as well (as in the re-
cently published 2010 GBD [40]).
Discounting takes account of the different time pe-
riods in which losses accrue. While future DALYs lost
Figure 2 Simplified representation of relevant time periods for future costs. Future losses occurring in the 1-year model cohort are discounted
to present value taking account of the time frames in which the losses occur.
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expected lifetime, future production losses occur only
during work-life, starting at the age of labor force par-
ticipation and ending with the end of work-life. Total
costs of the model can thus be interpreted as the present
value of all lifetime losses of the 1-year model cohort.
Sensitivity analysis
In order to test the robustness of our results and to
understand the influence of single model parameters we
run three types of sensitivity analysis (SA). First, we
carry out a deterministic SA by observing how results
change when each of the single model parameters is
modified by minus and plus 20% compared to the base
values. This type of analysis allows us to estimate the
importance of single parameters for model results.
Second, we explore consequences of modifications in
two key assumptions, namely the future wages, and the
effect of ZnD on mortality. Third, we carry out a
probabilistic SA by randomly varying all model parame-
ters within predefined distributions and then running
the model 10,000 times. The probabilistic SA allows us
to explore the interactions between the model parame-
ters and to evaluate a much larger range of parameter
variations than the deterministic SA. Table 2 reports the
types of distribution assumed for the single categories of
model parameters. Where information on the variabilityTable 2 Assumptions on distributions of model parameters
in probabilistic SA
Parameter Distribution
Unrestricted parameters, such as cognitive
score difference due to IDA
Normal
Non-negative parameters such as duration
of illnesses and risk estimates
Lognormal
Parameters with 0,1 range, such as disability
weights and share of IDA
Beta
Cost parameters Gammaof the parameters is not available from the literature, we
choose a SD equaling 20% of the mean.
Results
Model Population
The model population consists of all Filipino children
aged 6–59 months stratified by 10 SES and 2 age groups.
This population is modeled on the basis of the DHS
2008 population (60,901 individuals in 12,469 house-
holds) and extrapolated to the total population of
90,354,753 individuals [41]. Table 3 reports the esti-
mated number of children per SES and age group. The 9
million children are unevenly distributed among the SES
as poor households have a substantially higher number
of children than the wealthier households.
Table 4 shows child mortality and income by SES.
Child mortality in the lowest and the highest SES differ
by a factor of 3 for the children aged 6–23 months and
by a factor of 17 for the children aged 24–59 months.
Income distribution is strongly skewed towards the
higher SES with over half of income earned by the top 2
SES [42].
Prevalence of MNDs
The prevalence of IDA, VAD and ZnD in the model
population is calculated on the basis of hemoglobin,
serum retinol and serum zinc values measured in the
NNS [19] (Table 5 and Figure 3). Overall prevalence of
MNDs in the age group of 6-23-month-old children is
13% for IDA, 22% for VAD and 25% for ZnD. All MNDs
are markedly more prevalent in the lower SES. With a 4
times higher level of IDA in the poorest than the
wealthiest SES, this difference is particularly evident for
moderate IDA among 6-23-month-old children. The
contrast between SES is even stronger for severe IDA,
which is, however, relatively rare even in the children liv-
ing in the poorest households. Moderate IDA is substan-
tially lower in the group of 24-59-month-old children
Table 3 Model population (in 1,000 children) by SES and age group
Socio-economic strata 1 low 2 3 4 5 6 7 8 9 10 high Total
Children aged 6–23 months 403 348 344 354 310 271 299 265 233 234 3,061
Children aged 24–59 months 832 790 737 642 589 573 561 493 475 406 6,098
Percentage share of SES on total of children 6–59 months 13.5 12.4 11.8 10.9 9.8 9.2 9.4 8.3 7.7 7.0 100.0
Source: [18,41], own calculation.
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For VAD there is a twofold difference in prevalence be-
tween the lowest and the highest SES. Prevalence de-
creases only slightly as children grow older, and this
decrease is more marked among the children living in
wealthier households. ZnD has the highest overall preva-
lence but differs less between high and low SES and age
groups.
Health and cost consequences of MNDs
The epidemiological frameworks of adverse health conse-
quences due to IDA, VAD and ZnD (Figures 4, 5, and 6)
are based on an extensive literature review completed by
repeated consultations with the experts of our advisory
board. Wherever possible we drew information from pub-
lished systematic reviews of MN supplementation trials.
Tables 6, 7, and 8 show the effect sizes of the single
adverse health consequences and the dimension of re-
lated costs and disability weights. Connecting arrows in
Figures 4, 5, and 6 are labeled with numbers referring to
information contained in the Tables 6, 7, and 8 (table
and row number).
IDA leads to impaired cognitive development, low
physical activity and, in case of severe IDA, to increased
all-cause mortality (Figure 4). 60% of anemia measured
in the population is defined as IDA [27]. The impact on
cognitive development of 6-23-month-old children leads
to a substantial reduction of cognitive score in adult age
and a consequent loss in wages earned [8,43-45]. DALY
losses are calculated with the disability weights proposed
by Stein [46] as they distinguish between short term ef-
fects on low physical activity and the long term effects
of impaired cognitive development. Increased all-cause
mortality due to severe IDA leads to production losses
and DALY losses as the whole lifetime and income of
the children is lost.
VAD leads to a rise in the number of cases of diarrhea
and measles and increased all-cause mortality [47]. WeTable 4 Mortality and income distribution by SES
Socio-economic strata 1 low 2
Death per year per 1,000 children aged 6–23 months 10.2 8.2
Death per year per 1,000 children aged 24–59 months 3.5 2.8
Share of total income of SES on total income 1.8 2.9
Source: [18,42], own calculation.exclude xerophthalmia and blindness, because these
consequences of severe VAD are no longer observed in
the Philippines (expert knowledge of authors affiliated to
Philippines Food and Nutrition Research Institute).The
attribution of the number of cases of measles due to
VAD takes account of the SES specific rates of measles
vaccination. We assume that, in households where both
parents are working, diarrhea and measles lead to an ab-
sence from work of one of the parents for 2 days and
the consequent loss of income. Diarrhea and measles
also lead to direct medical costs and temporary DALY
losses. Increased all-cause mortality leads to long term
production and DALY losses.
ZnD leads to a rise in the number of cases of diarrhea
and respiratory disease, stunting and increased all-cause
mortality. Cost consequences of diarrhea and respiratory
disease are calculated as for VAD. The effect of ZnD on
mortality is unclear. An extensive review finds a signifi-
cant reduction in mortality risk when zinc is given alone
but no significant reduction when given in combination
with other nutrients [15]. We thus exclude an effect of
ZnD on mortality in our analysis. Stunting leads to lower
adult wages and DALY losses. The estimated effect of
stunting on adult wage varies widely with an additional
centimeter of adult height leading to an increase in
wages between 0.86% and 15.8% [48]. We base our esti-
mate on Gao and Smyth [49] which use more recent
data than other studies [48] and implement a validated
estimation strategy [50].
Costs of MNDs
Total lifetime costs of iron, vitamin A and zinc deficien-
cies in 6-59-month-old Filipino children amounted to
direct medical costs of 30 million dollars, production
losses of 618 million dollars and intangible costs of
122,138 DALYs (Table 9). These costs can be interpreted
as the lifetime costs of a 1-year cohort affected by
MNDs between the age of 6–59 months. The table also3 4 5 6 7 8 9 10 high Total
7.0 6.1 5.5 4.9 4.5 4.1 3.8 3.5 57.7
2.2 1.7 1.2 0.9 0.6 0.4 0.2 0.2 13.6
3.7 4.6 5.7 7.1 9.0 11.8 16.6 36.8 100
Table 5 Prevalence of MNDs by SES (%)
Socio-economic strata (SES)
Age group (months) 1 low 2 3 4 5 6 7 8 9 10 high Overall mean
Moderate IDA 6-23 20.92 18.67 16.51 14.47 12.57 10.82 9.23 7.80 6.54 5.42 13.13
24-59 4.81 4.43 4.07 3.73 3.42 3.12 2.85 2.60 2.35 2.14 3.54
Severe IDA 6-23 0.26 0.19 0.14 0.10 0.07 0.05 0.03 0.02 0.02 0.01 0.10
VAD 6-23 27.99 26.31 24.68 23.11 21.62 20.17 18.80 17.46 16.19 15.00 21.82
24-59 26.68 24.10 21.66 19.38 17.25 15.28 13.46 11.80 10.28 8.91 18.11
ZnD 6-23 31.51 29.76 28.06 26.42 24.82 23.27 21.78 20.35 18.97 17.65 25.00
24-59 28.72 27.82 26.94 26.08 25.25 24.39 23.57 22.76 21.97 21.20 25.39
Source: Own calculation, based on [19].
Overall mean is higher than mean of SES prevalence due to higher number of children in poorer households. No severe IDA in the 24–59 months age group.
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between the age of 6–23 months or between 24–
59 months.
Direct medical costs for treatment of diarrhea, respira-
tory disease and measles are dominated by costs due to
ZnD (89% of total). Production losses are dominated by
losses in future lifetime (90% of total), due to impaired
mental and physical development, and premature death
(10%) while current losses due to the absence of parents
from work when caring for their sick child appear to be
of minor importance (<1%). Intangible costs are mainly
due to premature death (47%) followed by future lifetime
losses (43% of total DALY losses) and losses in the
current year (10%).
Costs of IDA are mainly due to its impact on mental
development in 6-23-month-old children (100% of pro-
duction and 84% of DALY losses). The additional effect
of IDA in 24-59-month-old children is limited to DALY
losses due to reduced physical activity. As IDA has no
relevant direct effect on other diseases, it does not lead
to medical costs (medical costs of all-cause mortality are
not considered in the model). Costs of VAD areFigure 3 Prevalence of MNDs by SES and age group. Source: [36], ownpredominately caused by increased mortality of children
in both age groups (99% of production and 99% of
DALY losses). The main cost-effect of ZnD is on future
production losses due to stunting which amounts to 28%
of total production losses.
Costs of MNDs differ considerably between SES
(Table 10) as costs in the poorest third of the households
are 5 times higher than in the wealthiest third. These
differences are a result of both higher prevalence of
MNDs in lower SES as well as a higher number of young
children in poor households.
Results of sensitivity analysis
In the deterministic sensitivity analysis (SA) we first record
how results change as single model parameters are in-
creased or diminished by 20% and then summarize these
results in tornado diagrams, by ordering them from the lar-
gest to the smallest effect. Figure 7 displays the tornado dia-
grams for future production losses and intangible costs for
all the parameters that change the outcome by at least 1%.
Future production losses are most affected by the dis-
count rate applied to future losses. Changes in thecalculation. No severe IDA in the 24–59 months age group.
Figure 4 Health and cost consequences of IDA. Numbers refer to source of information of effect size or DALY weight in Tables 6, 7 and 8 (first
number identifies table). Dotted lines represent long term consequences.
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level have an almost one-to-one effect on production
losses. Further important factors are the parameters with
an impact on impaired cognitive development induced
by IDA.
Intangible costs are most affected by a change of the
discount rate applied to future DALY losses, as the
present value of DALYs far away in time is strongly re-
duced by discounting. For example 70 life years in full
health lost, equal to 70 DALYs lost, correspond to 29
DALYs at present value when discounted with a 3% rate.
Without discounting DALYs lost in future lifetime due
to impaired development and premature death would in-
crease by 138% and total DALYs by 125%. Intangible
costs are also strongly affected by changes in the param-
eters influencing the lifetime costs of IDA and the rela-
tive risk of mortality due to VAD.
Due to the high uncertainty regarding future wages,
we chose to evaluate two alternative scenarios: 1) Future
earnings corresponding to current SES specific earnings.
2) Future earning corresponding to median income (me-
dian income is lower than mean income as distributionFigure 5 Health and cost consequences of VAD. Numbers refer to sour
(first number identifies table). Dotted lines represent long term consequenof earnings is highly skewed with 53% of income in the
upper 20% of households). In both scenarios productiv-
ity losses are considerably reduced. Overall productivity
losses decrease by 37% in scenario 1 and by 36% in sce-
nario 2.
The systematic review that is the source of the effects
of ZnD on health provides two estimates of relative risks
for mortality. In the base case we use the estimate from
supplementation trials providing zinc in conjunction
with other micronutrients. For the sensitivity analysis we
also run our model using information on the RR derived
from supplementation trials where only zinc is tested
against a placebo. Based on these studies, the authors
find a RR for mortality of 1.22 [15]. When applying this
RR of mortality in our model, DALYs lost would increase
by 30% and production losses by 6%.
Probabilistic SA evaluates the overall variability of the
results by randomly varying all model parameters in
10,000 model runs. Figure 8 shows that intangible costs
were between 62,000 and 194,000 DALYs in 80% of the
model runs. Future production losses lay between 161
and 2,531 million dollars in 80% of the model runs, withce of information of effect size or DALY weight in Tables 6, 7 and 8
ces.
Figure 6 Health and cost consequences of ZnD. Numbers refer to source of information of effect size or DALY weight in Tables 6, 7 and 8
(first number identifies table). Dotted lines represent long term consequences.
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underlying parameter distributions.
Discussion
We present a health economic model simulating the life-
time cost consequences of iron, vitamin A and zinc defi-
ciencies in 6-59-month-old children in the Philippines
stratified in 10 SES and 2 age groups. The model in-
cludes a detailed representation of the consequences of
MNDs on health and physical and mental development.
Total lifetime costs amount to medical costs of 30 mil-
lion dollars, production losses of 618 million dollars andTable 6 Health consequences of MNDs
MND Health consequence Effect size (SD where available)
IDA Share of anemia caused by
iron deficiency
60%
Cognitive impairment and
motor development
Moderate or severe IDA in 6-23-mon
children: Cognitive score in adults re
by 9 points (on a scale with mean 1
Low physical activity Moderate or severe IDA: All children
All-cause mortality Moderate IDA: No effects
Severe IDA: RR of 2.21
VAD Diarrhea RR of 1.18 (1.15, 1.22)
Measles RR of 2.00 (1.49, 2.70)
All-cause mortality RR of 1.32 (1.20, 1.45)
ZnD Stunting Children 24–59 months: Height for a
is reduced by 0.17
Diarrhea RR of 1.25 (1.11, 1.41)
Respiratory diseases RR of 1.18 (1.03, 1.33)
All-cause mortality RR: 0.95 (0.81, 1.11). The model thus
no effect of ZnD on mortality.
Health consequences are assumed to be valid and equal for both age groups, with
due to IDA.intangible costs of 122,138 DALYs. Costs are dominated
by future lifetime costs due to impaired mental and
physical development (90% of production and 43% of
DALY losses) and costs of premature deaths (10% of
production and 47% of DALY losses) over current losses.
Burdens of MNDs differ substantially between SES as
the costs in the poorest third of the households are 5
times higher than in the wealthiest third. Intangible
costs are considerably higher for VAD and IDA than for
ZnD while direct medical costs are dominated by ZnD.
Production losses on the other hand are mainly deter-
mined by IDA, followed by ZnD. Nearly all the costs ofPersistent
effect
Numbering
in Figures 4,
5 and 6
Source Source
systematic
review
Not
applicable
6.1 [27,51] No
th-old
duced
00 and SD 15)
Yes 6.2 [43] No
No 6.3 [39,46] No
Yes 6.4 [52] Yes
No 6.5 [47] Yes
No 6.6 [47] Yes
Yes 6.7 [47] Yes
ge z-score Yes 6.8 [15] Yes
No 6.9 [15] Yes
No 6.10 [15] Yes
assumes Yes 6.11 [15] Yes
the exception of health impairments due to ZND and cognitive impairment
Table 7 Cost consequences adverse health effects
Effect size Numbering in
Figures 4, 5 and 6
Source
Productivity losses
Current Diarrhea, measles and
respiratory disease
2 days off work for 1 parent per episode of illness
(only if both work)
7. 1 Assumption
Parent off work Loss of daily gross wage of USD 1.1 -23.2 depending on SES 7.2 [53]
Future Impairment cognitive
development
1 SD reduction of the cognitive score leads to a
reduction of adult wage by 8%
7.3 [8,44]
Stunting 1% decrease in height leads to a reduction of adult
wage by 9.23% (average height in the Philippines is 158 cm)
7.4 [19,48,49,54]
Treatment costs per episode*
Current Diarrhea 9.6 USD 7.5 Calculation on DHS [18]
and PNHS [32]
Only complicated cases are treated (41% of cases in DHS)
Measles 92.7 USD 7.6 Calculation on DHS [18],
WHO [55] and PNHS [32]
By assumption only complicated cases are treated and
treatment costs are equal to those of respiratory
diseases (75% of cases) [56].
Respiratory disease 92.7 USD 7.7 Calculation on DHS [18]
and PNHS [32]
Only complicated cases are treated (60% of cases in DHS)
* Costs covered by health insurance companies and government agencies amount to 49% in addition to out-of-pocket expenditures by households registered
in DHS.
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http://www.biomedcentral.com/1471-2458/13/1167MNDs in the Philippines are incurred by households, as
they sustain a large share of medical costs and of the in-
come lost by parents looking after their sick children
and, most importantly, the huge income and DALY
losses borne by children in their future lifetime.
Magnitude of costs
It may be helpful to examine the magnitude of these re-
sults. The 122,138 DALYs lost are driven by the prema-
ture death of 1,951 child deaths corresponding to 57,569
DALYs lost. If we compare total DALYs lost with DALYs
lost due to premature death, we may conclude that the
equivalent of 4,000 complete lifespans are lost each year
because of MNDs. Comparing our undiscounted results
with the total undiscounted 22.2 million DALYs lost in
the Philippines in 2010 according to the GBD [57] the
share of DALYs lost due to MNDs amount to 1.24% ofTable 8 Disability weights of adverse health effects
Health consequence Disability weight Effect du
Cognitive impairment Moderate IDA: 0.006 Perman
Severe IDA: 0.024
Low physical activity Moderate IDA: 0.011 Tempo
Severe IDA: 0.087
Diarrhea 0.119 Tempo
Measles 0.152 Tempo
Respiratory disease 0.279 Tempo
Stunting 0.002 Perman
For ZnD and VAD they are obtained from the global burden of disease study by th
weights by type of disability [46].total DALYs lost. Health consequences include 5.6 million
days of diarrhea, 1.5 million days of respiratory disease
and 346,331 stunted children. Total monetary costs (direct
medical costs and production losses) amount to 648 mil-
lion dollars corresponding to 0.37% of GDP or 9.5% of
total private and public health care expenditures in the
Philippines in 2008 [58]. Although direct medical costs ap-
pear low in comparison to the other cost categories, they
can be substantial for poor households. The out-of-pocket
expenditure for the treatment of an episode of diarrhea
and lower respiratory disease, for example, amount to 6
and 62 dollars respectively while average weekly income of
the poorer half of households is at 11 dollars.
Strengths and limitations
To our knowledge, this is the first study combining the in-
formation on health and nutritional status of 6-59-month-ration Numbering in Figures 4, 5 and 6 Source
ent 8.1 [47]
rary 8.2 [47]
rary 8.3 [39]
rary 8.4 [39]
rary 8.5 [39]
ent 8.6 [39]
e WHO [39], while weights for IDA are provided by Stein, who distinguishes
Table 9 Total costs by cost category, MND, reference period (current, future) and age group
MND Medical cost
(million USD)
Production losses (million USD) Intangible costs (DALYs) Number of
premature
deaths
Within age group Age > 5 years Death Total Within age group Age > 5 years Death Total
Costs due to MNDs in 6–23 months old children
Iron 384.3 0.9 385.1 5′918 47′277 841 54′036 28
Vitamin A 1.8 0.5 38.7 39.2 394 37′976 38′370 1′284
Zinc 8.5 0.7 0.0 0.7 982 0 982 0
Total 10.3 1.2 384.3 39.6 425.1 7′294 47′277 38′817 93′389 1′313
Costs due to MNDs in children 24–59 months
Iron 2′373 6.8 2′380 0
Vitamin A 1.5 0.3 19.8 20.2 327 18′745 19′073 632
Zinc 18.5 1.1 171.8 0.0 173.0 2′032 5′264 0 7′297 0
Total 20.0 1.5 171.8 19.8 193.1 4′733 5′264 18′752 28′749 632
Costs due to MNDs in children 6–59 months
Iron 384.3 0.9 385.1 8′291 47′277 848 56′416 29
Vitamin A 3.3 0.8 58.6 59.4 722 56′721 57′443 1′923
Zinc 27.0 1.9 171.8 0.0 173.7 3′014 5′264 0 8′279 0
Total 30.3 2.7 556.1 59.4 618.2 12′027 52′542 57′569 122′138 1′951
Costs age > 5 years and death at present value (3% discount rate).
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http://www.biomedcentral.com/1471-2458/13/1167old children in the Philippines collected in two large and
representative surveys in 2008. We build a detailed and
transparent health economic model describing the lifetime
health and cost consequences of iron, vitamin A and zinc
deficiencies in these children. Prevalence of MNDs and
health and cost consequences are differentiated by 10 SES
and 2 age groups. The results are an important contribution
to the design, evaluation and choice of the most effective
and cost-effective policies aiming at the reduction of
MNDs. We carry out a comprehensive sensitivity analysis
in order to identify the parameters with the largest effect on
the results and to test the overall robustness of the model.
The model may in future be adapted to other countries.Table 10 Distribution of costs over SES by MND and cost cate
MND Cost category 1 low 2 3 4
IDA Production losses 82.44 62.81 51.93 54.34
DALYs lost 12,334 9,306 7,653 7,777
VAD Medical costs 0.72 0.57 0.47 0.41
Production losses 17.28 11.62 8.59 6.51
DALYs lost 16,802 11,277 8,349 6,327
ZnD Medical costs 5.66 4.66 3.88 3.32
Production losses 20.39 26.05 22.06 21.31
DALY lost 1,185 1,281 1,093 1,017
All Medical costs 6.37 5.23 4.35 3.73
Production losses 120.12 100.48 82.58 82.16
DALY lost 30,321 21,864 17,095 15,120
Medical cost and production losses in million USD, future costs and DALY losses atSome limitations have to be mentioned. First, our ap-
proach in identifying the health consequences of MNDs
via the results of micronutrient supplementation trials
has two potential caveats: The supplementation of
vitamin A and zinc in high doses may have a “pharmaco-
logical effect” which may lead to an overestimation of
the adverse health consequences. High doses of vitamin
A are for example employed in the treatment of measles,
malaria, diarrhea and respiratory diseases and high doses
of zinc are employed in the treatment of diarrhea in
children. However, some children with severe deficien-
cies and consequent health impairments are excluded
from supplementation trials as it would be unethical togory
Socio-economic strata
5 6 7 8 9 10 high Total
37.13 28.26 23.38 19.62 13.45 11.76 385.12
5,361 4,086 3,410 2,823 1,967 1,699 56,416
0.31 0.24 0.21 0.16 0.12 0.10 3.30
4.55 3.22 2.77 2.00 1.49 1.32 59.4
4,412 3,119 2,675 1,914 1,400 1,169 57,443
2.53 2.08 1.74 1.34 1.02 0.75 26.98
18.92 18.20 13.76 12.34 11.26 9.40 173.70
868 801 631 544 475 382 8,279
2.84 2.32 1.95 1.50 1.14 0.85 30.28
60.60 49.68 39.92 33.96 26.20 22.48 618.18
10,642 8,006 6,717 5,282 3,842 3,249 122,138
present value (3% discount rate).
Figure 7 Factors with strongest influence on intangible costs and future production losses. Grey bars indicate the consequence of an
increase of the parameter by 20%; black bars the effect of a decrease of 20%.
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http://www.biomedcentral.com/1471-2458/13/1167give these children a placebo supplement. This may lead
to an underestimation of the health consequences of
MNDs. These uncertainties are at least in part explored
in the probabilistic SA. Second, the consequences of
some MNDs can only be quantified with single studies
and not with systematic reviews. This is particularly the
case for the long-term consequences of IDA on cognitive
scores and the consequent reduction of adult wages.
Third, we compute future production losses with an
average future wage based on the current average wage
and the assumption of a constant productivity growthFigure 8 Results of probabilistic SA for future production losses and
future production losses and intangible costs. The solid vertical line represe
delimit the 80% confidence interval of the results of the probabilistic SA.rate. We thus assume that future wages of children will
converge to the average wage. We believe that this as-
sumption can be supported in face of the uncertainty of
the long-term development of a rapidly evolving emer-
ging country and the circumstance that lower current
wages in lower SES are in part due to the long term con-
sequences of malnutrition in childhood. In the sensitivity
analysis we show that dropping this assumption and as-
suming productivity growth rate adjusted future wages
equal to the current SES specific wages would reduce
production losses by 37%.intangible costs. The curves indicate the cumulative distribution of
nts the main results of the model while the dotted vertical lines
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http://www.biomedcentral.com/1471-2458/13/1167Comparison with previous research
Our results appear in line with most results of previous
studies although a comparison is often difficult because
of differences in population, cost-categories, micronutri-
ents and countries considered. A direct comparison can
be made with 2 studies which include the calculation of
the costs of MNDs in the Philippines: Zimmermann and
Qaim [59] examined the DALY losses due to VAD in
children below 7 years of age in the Philippines based on
NNS data of 1993 and 1998. They calculate a loss of
139,518 DALYs in children due to mortality and disabil-
ity caused by VAD. This loss is higher than the 57,443
DALYs lost due to VAD in 2008 according to our study.
The divergence can, however, at least in part be ex-
plained by the difference in the populations (we do not
include 0–5 and 60-84-month-old children) and the de-
crease in the prevalence of VAD in the Philippines over
the previous 10–15 years which led to the elimination of
some severe health consequences of VAD such as night-
blindness, Bitot’s spots and corneal scars. A study by
Meenakshi et al. [60] estimates losses of 70,000 DALYs
due to VAD and of 80,000 DALYs due to ZnD for
Filipino children below the age of 6 years based on sur-
veys carried out in the 1990s and early 2000s.
An apparent difference between our results and those
of previous studies is the lower magnitude of DALY
losses due to ZnD (7% of total DALY losses in our study)
in comparison to those of VAD (47%) and IDA (46%). In
the important study by Black et al. [4], distribution of
global DALY losses among these MNDs looks, for ex-
ample, quite different with 40% of losses attributed to
ZnD, 55% to VAD and only 5% to IDA. Apart from dif-
ferences in the populations and countries considered,
the higher DALY losses due to IDA in our study are
mainly due to the inclusion of DALY losses attributed to
impaired cognitive development, while the lower share
of losses due to ZnD is mainly due to the absence of an
impact of ZnD on mortality. This absence of an impact
on mortality is based on the findings of a recent system-
atic review of zinc supplementation trials [15], which
shows no significant effect of zinc on mortality when
given in conjunction with other micronutrients.
Policy implications
Our results show that the costs of MNDs are highly con-
centrated in the lower SES and the younger age group of
children. Costs are 5 times higher in the poorest third of
households than in the wealthiest third. The difference
in cost per child between the 6-23-month age group and
the 24-59-month age group is even larger with a 4.4-fold
difference in production losses and a 6.5-fold difference
in intangible costs. These results are important because
interventions focusing on the SES and the age classes
with most severe deficiencies and highest costs are likelyto have a higher health impact and to be more cost-
effective.
The invisible or hidden nature of the costs of MNDs is
particularly apparent for IDA, as 84% of DALY losses
and nearly all production losses occurring in future life-
time are triggered by IDA between 6 and 23 months of
age. Without any specific knowledge of the links be-
tween nutrition and future cognitive development of
their child, the parents will have no reason to improve
the diet of the child. The reasons why parents do not in-
vest sufficiently in the future health of their children al-
though the cost of prevention appears small relative to
its future benefits have, for example, been investigated in
the research on the use of mosquito nets for malaria
prevention [61] or vaccinations [62]. Policies aimed at
reducing MNDs in children living in poor households
should take account of the informational, behavioural
and economic obstacles highlighted in this literature.
The much higher prevalence of MNDs in lower SES
may be one of the factors leading to a health-based pov-
erty trap [63]. Because of inadequate nutrition, children
of the poor are more likely to be ill with diarrhea and re-
spiratory infections. Their families will have to spend
more on medical care and may not be able to provide
them with adequate care. Due to the impact of MNDs
on physical and cognitive development, many of these
children will not be able reach their full potential and
become poor parents in their later life.
Conclusions
MNDs lead to substantial costs in 6-59-month-old chil-
dren in the Philippines. These costs are dominated by
future production losses and intangible costs. Costs are
highly concentrated in the lower SES and in 6-23-
month-old children. These results may have important
implications for the design, evaluation and choice of the
most effective and cost-effective policies aimed at the re-
duction of MNDs.
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